The first human trial of a novel class of anticoagulants shown to be as effective as blood thinners like Xarelto and Eliquis but with much fewer adverse bleeding effects is scheduled to begin soon in Australia. The new class has successfully completed regulatory toxicology studies and was well-tolerated after a 28-day repeat dosing. VE-1902, developed by Verseon, is in a new class of drugs called PRecision Oral AntiCoagulants, or PROACs. If results of clinical trials are favorable, V-1902 could have a major impact on the treatment of cardiovascular diseases by becoming the first blood thinner suitable for long-term anticoagulation-antiplatelet combination ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.